XAUUSD: Elliott wave analysis and forecast for 30.08.24 – 06.09.24

2024.08.30 2024.08.30 XAUUSD: Elliott wave analysis and forecast for 30.08.24 – 06.09.24 Alex Geutahttps://www.litefinance.org/blog/authors/alex-geuta/ The article covers the following subjects: Highlights and key points Main scenario: consider long positions from corrections above the level of 2471.10 with a growth target of 2600.00 – 2700.00. A buy signal: if the price remains above 2471.10. Stop Loss: below 2440.00, Take Profit:…

Read more

5 Common Trading Biases You Might Be Unaware Of

Having trading biases can severely impair our ability to read the markets objectively and make good trading decisions. The first step to overcoming these biases is to become fully aware of them. Here are five of the most common forex trading biases. Which ones are you guilty of? 1. Recency bias Do you often find yourself zoning in on…

Read more

Forexlive European FX news wrap 30 Aug – Eurozone CPI in line with expectations

High risk warning: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all your initial investment; do not invest money that you…

Read more

Set to test the 0.6820 resistance – UOB Group

The Australian Dollar (AUD) is expected to trade in a range, probably between 0.6775 and 0.6820. In the longer run, there has been no further increase in momentum; if AUD breaks below 0.6730, it would mean that 0.6870 is not coming into view, UOB Group FX analysts Quek Ser Leang and Lee Sue Ann notes. Moves up towards 0.6820…

Read more

Pfizer (PFE) Stock Price Forecast for 2024, 2025, 2026-2030, and Beyond

2024.08.30 2024.08.30 (PFE) Pfizer Stock Price Forecast: 2024 and Beyond Jana Kanehttps://www.litefinance.org/blog/authors/jana-kane/ In the ever-evolving pharmaceutical landscape, Pfizer (NYSE: PFE) is a key player, with its stock forecast garnering significant interest from investors and analysts alike. Heading into 2024 and beyond, the consensus tilts towards a cautiously optimistic outlook for Pfizer’s stock. This optimism is underpinned by the company’s…

Read more

U.S. Q2 2024 GDP Revised Higher Thanks to Stronger Consumer Spending

The second version of the U.S. GDP reading was upgraded to show a faster 3.0% expansion in Q2 2024 versus the initially reported 2.8% figure. This also reflected a significant acceleration in economic growth compared to the Q1 2024 GDP of 1.4%. The positive revision to the preliminary GDP reading mostly came from higher consumer spending on services and…

Read more

ECB's Schnabel urges caution and emphasizes data-driven policy

ECB’s Schnabel: Incoming data have broadly confirmed the baseline outlook. ECB’s Schnabel: Confidence is not knowledge. History will not judge our intentions but our success in delivering on our mandate. ECB’s Schnabel: The closer policy rates get to the upper band of estimates of the neutral rate of interest, the more cautious we should be to avoid that policy…

Read more

Chart Art: EUR/NZD Long-Term Range Support

After getting rejected on its long-term range resistance, EUR/NZD now seems to have its sights set back on testing support. Will the floor hold again? Take a look at these inflection points I’m watching on the daily time frame: EUR/NZD Daily Forex Chart by TradingView A combination of risk-on flows and relatively upbeat data from New Zealand seem to…

Read more

Mostly messy day for sentiment so far

Sentiment is a bit mixed across markets this morning. FX: In FX we have the JPY (safe haven) leading the pack after a better-than-expected Tokyo CPI number, with the AUD and NZD (high betas) second and third strongest. The EUR is leading the pack on the downside, most likely still due to the big deceleration we saw in German…

Read more